



2021 CCS Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

Panel Member's Relationships with Industry (RWI)

The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of relationships with industry (RWI). Panel members must disclose all relationships with industry regardless of relevance to the statement topic (see below). When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Primary Panel				
Glen Pearson	None	None	None	
George Thanassoulis	Amgen, Sanofi, HLS therapeutics, Novartis, servier, silence	Amgen, Novartis,	Research grants: Ionis, Servier	
Todd Anderson	None	Dal-cor, Novartis	None	
Arden Barry	None	None	None	
Patrick Couture	Amgen, Merck, Sanofi, Kaneka Corporation	Amgen, Sanofi	None	These are corporations marketing lipid-lowering drugs. Clinical trials testing new lipid-lowering drugs
Natalie Dayan	None	None	None	
Gordon Francis	None	Akcea Pharmaceuticals	None	Treatment of hypertriglyceridemia only in very severe cases. Not likely to have any bearing on the guidelines.
Jacques Genest Jr	Amgen, Sanofi	Amgen, Sanofi	None	Advisory Board. Trials ended in 2018. Involved as Chair with FHCanada, support from biopharmaceutical companies.
Jean Grégoire	Amgen, Bayer, BMS/Pfizer Alliance, Boehringer Ingelheim, HLS Therapeutics, Novartis, Sanofi, Servier	None	None	Almost all hypolipemic medications are generic. I intend to provide an unbiased, objective, evidence-based approach to the development and revision of guideline/position statement.
Steven Grover	Merck Canada, HLS Therapeutics		None	I have provided consultation to HLS and Merck
Milan Gupta	Amgen, HLS, Novartis	None	None	Companies marketing lipid-lowering drugs
Robert Hegele	Aegerion, Amgen, Arrowhead, Sanofi, Ionis-Akcea, Pfizer, Regeneron	Amgen, Medicines Company, Sanofi	None	Pharmaceutical companies that market or are developing lipid-lowering medications. Trials of investigational lipid-lowering therapies.

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
David C. W. Lau	Amgen, AstraZeneca, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, CME at Sea, Eli Lilly, HLS Therapeutics, Janssen, Novartis, Novo Nordisk, Sanofi	Novo Nordisk	None	I intend to provide an unbiased, objective, evidence-based approach to the development and revision of guideline/position statement. The clinical trials are multi-centre, double-blinded, randomized, placebo-controlled cardiovascular outcome trials in obesity, and efficacy and safety of subcutaneous semaglutide 2.4 mg once-weekly in subjects with obesity and prediabetes
Lawrence Leiter	Amarin, Amgen, AstraZeneca, Esperion, HLS Therapeutics, Merck, Novartis, Sanofi	Amgen, Esperion, Kowa, Novartis, The Medicines Company	None	Manufacturers of Lipid Lowering Drugs
Alexander Leung	None	None	None	No relevance to guidelines
Eva Lonn	Amgen, Bayer, Boehringer Ingelheim, HLS therapeutics, Novartis, Sanofi	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi	None	Consulting fees not related to development of guidelines
GB John Mancini	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Janssen, Merck, Novartis, NovoNordisk, Sanofi, Servier, Esperion, HLS Therapeutics	Amgen, NovoNordisk, Novartis	None	Makers or developers of lipid lowering medications. Studies pertain to management of dyslipidemia, metabolic syndrome, diabetes.
Priya Manjoo	Amgen, Bausch Health, Myaln, NovoNordisk, Sanofi,	None	None	I have received consulting fees from Novonordisk and Bausch Health for consulting in the field of Obesity. I have also attended Advisory Boards on osteoporosis medications for Amgen. Honoraria for guideline-related talks at educational forums (some supported by HLS).
Ruth McPherson	Amgen, HLS Therapeutics, Novartis, Pendopharm	Novartis	Grants/Research Support: Amgen, Astra Zeneca, BI, Novartis	These are corporations marketing lipid-lowering or cardiovascular protective drugs. Clinical trials testing new lipid-lowering drugs

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Daniel Ngui	Amgen, Astra Zeneca, BMS, Boehringer Ingelheim, Eli Lilly, Novonordisk	Amgen, CHRC, Kaiser Permanente, Servier	Grants/Research Support: Amgen, Astra Zeneca, Boehringer Ingelheim, Novartis Physician CME Organizations: CPD Network and Alliance for Best Practices in Health Education	Some of of the companies I work with have products in therapeutic areas where cholesterol is important eg Diabetes. Some of the companies I do advisory board work for have products in dyslipidemia eg. Amgen so I would recuse voting on affected areas. The two trials are in osteoporosis and hypertension so it should not affect me.
Marie-Eve Piché	None	None	None	
Paul Poirier	Abbott Canada, Amgen, AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, NovoNordisk, Sanofi, Servier, Valeant	Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Servier	None	I am exchanging with company involves in lipid management. I was local principal investigation in trial involving company in lipid management.
John Sievenpiper	American Society for Nutrition (ASN), Dairy Farmers of Canada, Nestlé, Abbott, General Mills, Nutrition Communications, International Food Information Council (IFIC), Calorie Control Council, International Glutamate Technical Committee, Perkins Coie LLP, Tate & Lyle, Danone, Inquis Clinical Research, European Fruit Juice Association (AIJN), Soy Nutrition Institute (SNI)	Canadian Foundation for Innovation, Ontario Research Fund, Province of Ontario Ministry of Research and Innovation and Science, Canadian Institutes of health Research (CIHR), The Glycemic Control and Cardiovascular Disease in Type 2 Diabetes Fund at the University of Toronto (a fund established by the Alberta Pulse Growers), The Nutrition Trialists Fund at the University of Toronto (a fund established by the Calorie Control Council), Almond Board of California, California Walnut Commission, Peanut Institute, Barilla, Upfield, Unico/Primo, Loblaw Companies, Quaker, Kellogg Canada, Danone, Nutrartis, Dairy Farmers of Canada	Diabetes Canada, PSI Foundation, Banting and Best Diabetes Centre (BBDC), American Society for Nutrition (ASN), INC International Nut and Dried Fruit Council Foundation, National Honey Board (the U.S. Department of Agriculture [USDA] honey "Checkoff" program), Institute for the Advancement of Food and Nutrition Sciences (IAFNS; formerly ILSI North America), Pulse Canada, Quaker Oats Center of Excellence	Food and ingredient companies, trade asocations, health charities, insitutions, non-governmental and governmental organzations with an interest in nutrition and non-comunicable diseases.
James Stone	None	None	None	None
Richard Ward	Amgen, AstraZeneca, BMS Pfizer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Aliiance, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, NovoNordisk, Otsuka, Pfizer, Servier, Takeda	AstraZeneca, Eli Lilly	None	I have not been on any 'lipid specific' groups associated with these companies. HOPE 3 did look at statins in primary prevention. REWIND is DM trial.
Wendy Wray	None	None	None	No relevance to guidelines

Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this statement.

Member	Consulting Fees/ Honoraria	Clinical Trials	Other Financial Benefit	Relevance to Statement
Secondary Panel				
Ranjani Aiyar	None	None	None	
Alexis Baass	Amgen, Sanofi	Amgen, Sanofi, Medicines Company, Akcea	None	I have participated in advisory boards of companies that market or are developing lipid-lowering medications. I have worked on clinical trials of investigational lipid-lowering therapies.
N. John Bosomworth	None	None	None	
Liam Brunham	Amgen, HLS, Novartis, Sanofi, Amryt	Novartis	None	
Alice Y. Y. Cheng	Abbott, Astra Zeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Insulet, HLS Therapeutics, Janssen, Medtronic, Merck, Novartis, Novo Nordisk, Sanofi, Takeda	Applied Therapeutics	None	
Dan Dattani	Eli Lilly, Bayer, Pfizer	None	None	No relevance to guidelines
Ross Feldman	Medtronic, Novartis	Quantum	None	No relevance to guidelines
Geoff Lewis	None	None	None	
Karen Then	None	None	None	
Sheldon Tobe	Astra Zeneca, Bayer, Boehringer Ingelheim	Bayer, AbbVie	None	No relevance to guidelines